Skip to main
  1. Stocks
  2. Rani Therapeutics Holdings
  3. Forecast
RANI

RANI Stock Forecast & Price Target

RANI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rani Therapeutics Hldgs is positioned favorably because its RaniPill platform has repeatedly shown clinically meaningful oral delivery across four studies and more than 250 capsules, with RT-114 achieving greater than 150% relative bioavailability versus matched subcutaneous dosing and no serious or capsule-attributed adverse events. That human PK validation materially de-risks the core technology, while the broader dataset across peptides, proteins, antibodies, and large payloads suggests the platform could support multiple partnered programs rather than a single asset. Financially, the company looks adequately funded for near-term catalysts, ending June with $53.4 million in cash, cash equivalents and marketable securities, while R&D of $5.0 million and EPS of $(0.04) were both better than FactSet expectations, supporting execution through the planned YE26 and 2027 milestones.

Bears say

Rani Therapeutics Hldgs is viewed negatively because the core investment case still depends on an unproven human pharmacodynamic link: while the company has built a compelling human PK dataset, it has not yet shown that RaniPill-delivered exposure produces meaningful efficacy in humans. The evidence base remains limited by small cohorts and short-duration studies, leaving uncertainty around repeat-dose tolerability, durability, and the magnitude of benefit in RT-114 Phase 1b. Even if the platform works technically, commercialization remains uncertain versus increasingly convenient injectable alternatives, and the company’s history of capital constraints and shifting priorities makes scaling dependent on securing partners or additional funding.

RANI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.

RANI Analyst Forecast & Price Prediction

Get the latest RANI stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in RANI

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rani Therapeutics Holdings (RANI) Forecast

Analysts have given RANI a Strong Buy based on their latest research and market trends.

According to 3 analysts, RANI has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rani Therapeutics Holdings (RANI)


RANI Analyst Forecast & Price Prediction

Get the latest RANI stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in RANI

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover RANI stock data and trends